Fate Therapeutics
NASDAQ: FATESan Diego, US · Delaware corporation · 3 known investors
Fate Therapeutics develops clinical-stage cell therapy drug candidates for autoimmune diseases and cancer, using an induced pluripotent stem cell (iPSC) platform to create off-the-shelf, multiplexed-engineered cell products. Its therapies aim to overcome manufacturing and commercialization limitations of conventional cell therapies.
BiotechHealthtech
Founders & leadership
CW
Christian WeyerExecutive
JS
J. Scott WolchkoExecutive
DS
Daniel ShoemakerExecutive
Board
AN
Amir Nashatin𝕏Board directorEntrepreneur partner at Polaris Partners focused on healthcare investing and portfolio company executive roles
JM
John MendleinBoard director
WR
William RastetterBoard director
ME
Mark EnyedyBoard director
TC
Timothy CoughlinBoard director
RE
Robert EpsteinBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$175M disclosed across 5 rounds · 2015–2020
▶$50MraisedJul 2020 · 1 investors · BiotechnologyRule 506(b)
▶$50MraisedJul 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shefali AgarwalDirector
- Cindy TahlExecutive Officer
- Karin JoossDirector
- Robert HershbergDirector
- J. Scott WolchkoExecutive Officer, Director
- William RastetterDirector
- Timothy CoughlinDirector
- Michael LeeDirector
- John MendleinDirector
- Robert EpsteinDirector
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50MraisedApr 2020 · 1 investors · BiotechnologyRule 506(b)
▶$50MraisedApr 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert EpsteinDirector
- J. Scott WolchkoExecutive Officer, Director
- Shefali AgarwalDirector
- Michael LeeDirector
- John MendleinDirector
- Cindy TahlExecutive Officer
- William RastetterDirector
- Karin JoossDirector
- Timothy CoughlinDirector
- Amir NashatDirector
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$56.7MraisedDec 2016 · 21 investors · BiotechnologyRule 506(b)
▶$56.7MraisedDec 2016 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JOHN MENDLEINDirector
- ROBERT S. EPSTEINDirector
- CINDY TAHLExecutive Officer
- J. SCOTT WOLCHKOExecutive Officer, Director
- MARK J. ENYEDYDirector
- WILLIAM RASTETTERDirector
- TIMOTHY P. COUGHLINDirector
- CHRIS STORGARDExecutive Officer
- AMIR NASHATDirector
- STEWART ABBOTExecutive Officer
- DANIEL D. SHOEMAKERExecutive Officer
- Offering amount
- $56.7M
- Amount sold
- $56.7M
- Sales commissions
- $1.7M
- Placement agents
- LEERINK PARTNERS LLC
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.3MraisedAug 2016 · 4 investors · BiotechnologyRule 506(b)
▶$10.3MraisedAug 2016 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- DANIEL D. SHOEMAKERExecutive Officer
- ROBERT S. EPSTEINDirector
- WILLIAM RASTETTERDirector
- JOHN MENDLEINDirector
- STEWART ABBOTExecutive Officer
- MARK J. ENYEDYDirector
- TIMOTHY P. COUGHLINDirector
- AMIR NASHATDirector
- CHRIS STORGARDExecutive Officer
- J. SCOTT WOLCHKOExecutive Officer, Director
- CINDY TAHLExecutive Officer
- Offering amount
- $10.3M
- Amount sold
- $10.3M
- First sale
- Aug 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedMay 2015 · 1 investors · BiotechnologyRule 506(b)
▶$8MraisedMay 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Amir NashatDirector
- John MendleinDirector
- Christian WeyerExecutive Officer, Director
- William RastetterDirector
- J. Scott WolchkoExecutive Officer
- Mark EnyedyDirector
- Daniel ShoemakerExecutive Officer
- Timothy CoughlinDirector
- Robert EpsteinDirector
- Offering amount
- $8M
- Amount sold
- $8M
- First sale
- May 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapKite Pharma36 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Bioworld36 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Fate Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Fate Therapeutics do?
- Fate Therapeutics develops clinical-stage cell therapy drug candidates for autoimmune diseases and cancer, using an induced pluripotent stem cell (iPSC) platform to create off-the-shelf, multiplexed-engineered cell products. Its therapies aim to overcome manufacturing and commercialization limitations of conventional cell therapies.
- Who are Fate Therapeutics's investors?
- Fate Therapeutics's investors include Sanofi Ventures, Venrock, Polaris Partners.
- How much funding has Fate Therapeutics raised?
- Fate Therapeutics has disclosed $175M raised across 5 rounds.
- Where is Fate Therapeutics headquartered?
- Fate Therapeutics is headquartered in San Diego, US.